Vis enkel innførsel

dc.contributor.authorFrøyland, Livar
dc.contributor.authorHaugen, Margaretha
dc.contributor.authorHolvik, Kristin
dc.contributor.authorLøvik, Martinus
dc.contributor.authorStrand, Tor A
dc.contributor.authorTell, Grethe S.
dc.contributor.authorIversen, Per Ole
dc.coverage.spatialNorwaynb_NO
dc.date.accessioned2018-04-27T11:31:20Z
dc.date.available2018-04-27T11:31:20Z
dc.date.created2017-10-19T09:31:56Z
dc.date.issued2016
dc.identifier.isbn978-82-8259-196-6
dc.identifier.urihttp://hdl.handle.net/11250/2496378
dc.description.abstractAt the request from the Norwegian Food Safety Authority (NFSA), the Norwegian Scientific Committee on Food Safety (VKM) has characterised the risk of specified doses of Lphenylalanine and DL-phenylalanine in food supplements. VKM concludes that: • In adults (≥ 18 years), the specified doses 100, 250, 500, 750 and 1000 mg/day Lphenylalanine in food supplements are considered unlikely to cause adverse health effects. • In adolescents (14 to < 18 years), the specified doses 100, 250, 500, 750 and 1000 mg/day L-phenylalanine in food supplements are considered unlikely to cause adverse health effects. • In children (10 to < 14 years), the specified doses 100, 250, 500, 750 and 1000 mg/day L-phenylalanine in food supplements are considered unlikely to cause adverse health effects. Although the highest dose provides 23 mg/kg bw per day which slightly exceeds 22.4 mg/kg bw per day, it is considered unlikely to cause adverse health effects in healthy children 10 to < 14 years. • None of the above conclusions are applicable for patients with phenylketonuria (PKU). • No conclusion can be made regarding DL-phenylalaninenb_NO
dc.language.isoengnb_NO
dc.publisherNorwegian Committee for Food Safetynb_NO
dc.relation.ispartofVKM Report
dc.relation.ispartofseriesVKM Report;
dc.relation.urihttps://vkm.no/download/18.645b840415d03a2fe8f26065/1502799816007/72d7a82d8d.pdf
dc.rightsNavngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/deed.no*
dc.subjectAdverse health effectnb_NO
dc.subjectphenylalaninenb_NO
dc.subjectfood supplementnb_NO
dc.subjectnegative health effectnb_NO
dc.subjectNorwegian Scientific Committee for Food Safetynb_NO
dc.subjectother substancesnb_NO
dc.subjectrisk assessmentnb_NO
dc.subjectVKMnb_NO
dc.titleRisk assessment of "other substances" – L-phenylalanine and DL-phenylalanine. Opinion of the Panel on Nutrition, Dietetic Products, Novel Food and Allergy of the Norwegian Scientific Committee for Food Safetynb_NO
dc.typeResearch reportnb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber34nb_NO
dc.source.issue6nb_NO
dc.identifier.cristin1505778
cristin.unitcode1991,0,0,0
cristin.unitnameSykehuset Innlandet HF
cristin.ispublishedtrue
cristin.fulltextoriginal


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal